Regenerative approaches to post-myocardial infarction heart failure

Current Pharmaceutical Design

Volumn 20, Issue 12, 2014, Pages 1930-1940

  Martin, Kenneth ^a   Huang, Chien Ling ^a   Caplice, Noel M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Cardiac regeneration; Paracrine; Stem cells; Tissue engineering

Indexed keywords

ACTIVIN A; BONE MORPHOGENETIC PROTEIN 4; CARDIAC MYOSIN; CARDIOLIPIN; DELCASERTIB; FIBROBLAST GROWTH FACTOR 2; FRACTALKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASE; MYELOPEROXIDASE; PROTEIN KINASE C DELTA; RETINOIC ACID; SOMATOMEDIN C; THROMBIN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CARDIAC CELL THERAPY; CARDITIS; CD8+ T LYMPHOCYTE; CELL CONTACT; CELL DEATH; CELL DIFFERENTIATION; CELL THERAPY; CHROMOSOME NUMBER; CYTOKINE RELEASE; ENDOTHELIAL PROGENITOR CELL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART REGENERATION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; ISCHEMIC HEART DISEASE; MACROPHAGE; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; NEUTROPHIL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; POST MYOCARDIAL INFARCTION HEART FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATION; SCAR FORMATION; SOMATIC CELL; STEM CELL NICHE; TISSUE ENGINEERING; UPREGULATION; VASCULAR ENDOTHELIUM; VIRAL GENE DELIVERY SYSTEM; ANIMAL; COMPLICATION; HEART VENTRICLE REMODELING; MYOCARDIAL INFARCTION; PATHOLOGY; PHYSIOLOGY; PROCEDURES; STEM CELL TRANSPLANTATION; TRENDS;

ANIMALS; APOPTOSIS; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; REGENERATION; STEM CELL TRANSPLANTATION; VENTRICULAR REMODELING;

EID: 84898618681     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990450     Document Type: Article

References (140)

1. Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008; 118(20): 2057-62.
2. White HD, Chew DP. Acute myocardial infarction. Lancet 2008; 372(9638): 570-84.
3. Anversa P, Leri A, Beltrami CA, Guerra S, Kajstura J. Myocyte death and growth in the failing heart. Lab Invest 1998; 78(7): 767-786.
4. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJ. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 2007; 74(3): 343-355.
5. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357(11): 1121-1135.
6. Investigators DIoS-PKCEtLTISiAMI. Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. Circulation 2008; 117(7): 886-96.
7. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 2003; 60(3): 617-25.
8. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfu-sion injury in acute myocardial infarction. N Engl J Med 2008; 359(5): 473-81.
9. Chugh AR, Beache GM, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012; 126(11 Suppl 1): S54-64.
10. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012; 379(9819): 895-904.
11. Carmeliet P, Collen D. Transgenic mouse models in angiogenesis and cardiovascular disease. J Pathol 2000; 190(3): 387-405.
12. Li RK, Weisel RD, Mickle DA, et al. Autologous porcine heart cell transplantation improved heart function after a myocardial infarction. J Thorac Cardiovasc Surg 2000; 119(1): 62-8.
13. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013.
14. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 2010; 121(22): 2437-45.
15. Tomita S, Li RK, Weisel RD, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999; 100(19 Suppl): II247-II56.
16. Tomita S, Mickle DA, Weisel RD, et al. Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg 2002; 123(6): 1132-40.
17. Reinecke H, Murry CE. Taking the death toll after cardiomyocyte grafting: a reminder of the importance of quantitative biology. J Mol Cell Cardiol 2002; 34(3): 251-3.
18. Doyle B, Kemp BJ, Chareonthaitawee P, et al. Dynamic tracking during intracoronary injection of 18F-FDG-labeled progenitor cell therapy for acute myocardial infarction. J Nucl Med 2007; 48(10): 1708-14.
19. Assmus B, Rolf A, Erbs S, et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010; 3(1): 89-96.
20. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011; 306(19): 2110-9.
21. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11(4): 367-8.
22. Doyle B, Sorajja P, Hynes B, et al. Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta1. Stem Cells Dev 2008; 17(5): 941-51.
23. Kumar AH, Caplice NM. Clinical potential of adult vascular progenitor cells. Arterioscler Thromb Vasc Biol 2010; 30(6): 1080-7.
24. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999; 277(1 Pt 1): C1-9.
25. O'Sullivan JF, Leblond AL, Kelly G, et al. Potent long-term cardioprotective effects of single low-dose insulin-like growth factor-1 treatment postmyocardial infarction. Circ Cardiovasc Interv 2011; 4(4): 327-35.
26. Vilahur G, Juan-Babot O, Pena E, Onate B, Casani L, Badimon L. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol 2011; 50(3): 522-33.
27. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204(12): 3037-47.
28. Hynes B, Kumar AH, O'Sullivan J, et al. Potent endothelial progenitor cell-conditioned media-related anti-apoptotic, cardiotro-phic, and pro-angiogenic effects post-myocardial infarction are mediated by insulin-like growth factor-1. Eur Heart J 2011.
29. Liu TB, Fedak PW, Weisel RD, et al. Enhanced IGF-1 expression improves smooth muscle cell engraftment after cell transplantation. Am J Physiol Heart Circ Physiol 2004; 287(6): H2840-9.
30. Debinski M, Buszman PP, Milewski K, et al. Intracoronary adi-ponectin at reperfusion reduces infarct size in a porcine myocardial infarction model. Int J Mol Med 2011; 27(6): 775-81.
31. Lynch P, Lee TC, Fallavollita JA, Canty JM, Jr., Suzuki G. Intra-coronary administration of AdvFGF-5 (fibroblast growth factor-5) ameliorates left ventricular dysfunction and prevents myocyte loss in swine with developing collaterals and ischemic cardiomyopathy. Circulation 2007; 116(11 Suppl): I71-6.
32. Tao Z, Chen B, Tan X, et al. Coexpression of VEGF and angio-poietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart. Proc Natl Acad Sci U S A 2011; 108(5): 2064-9.
33. Lichtenauer M, Mildner M, Hoetzenecker K, et al. Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myo-cardial infarction: a preclinical study. Basic Res Cardiol 2011; 106(6): 1283-97.
34. Chen TS, Lai RC, Lee MM, Choo ABH, Lee CN, Lim SK. Mesen-chymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Research 2010; 38(1): 215-24.
35. Hansen PR. Inflammatory alterations in the myocardial microcircu-lation. J Mol Cell Cardiol 1998; 30(12): 2555-9.
36. Panizzi P, Swirski FK, Figueiredo JL, et al. Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol 2010; 55(15): 1629-38.
37. Arslan F, de Kleijn DP, Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 2011; 8(5): 292-300.
38. Bernardo A, Ball C, Nolasco L, Moake JF, Dong J-F. Effects of inflammatory cytokines on the release and cleavage of the endothe-lial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104(1): 100-6.
39. Li W, Nava RG, Bribriesco AC, et al. Intravital 2-photon imaging of leukocyte trafficking in beating heart. J Clin Investigation 2012; 122(7): 2499-508.
40. Schulz C, Schafer A, Stolla M, et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116(7): 764-73.
41. Nichols TC, Bellinger DA, Reddick RL, Read MS, Koch GG, Brinkhous KM, et al. Role of von Willebrand factor in arterial thrombosis. Studies in normal and von Willebrand disease pigs. Circulation 1991; 83(6 Suppl): IV56-IV64.
42. van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. J Exp Med 1968; 128(3): 415-35.
43. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007; 317(5838): 666-70.
44. Murry CE, Field LJ, Menasche P. Cell-based cardiac repair: reflections at the 10-year point. Circulation 2005; 112(20): 3174-83.
45. Pinto AR, Paolicelli R, Salimova E, et al. An abundant tissue macrophage population in the adult murine heart with a distinct alternatively-activated macrophage profile. PLoS One 2012; 7(5): e36814.
46. Tsujioka H, Imanishi T, Ikejima H, et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 2009; 54(2): 130-8.
47. Jankowski M, Bissonauth V, Gao L, et al. Anti-inflammatory effect of oxytocin in rat myocardial infarction. Basic Res Cardiol 2010; 105(2): 205-18.
48. Doesch AO, Mueller S, Nelles M, et al. Impact of troponin I-autoantibodies in chronic dilated and ischemic cardiomyopathy. Basic Res Cardiol 2011; 106(1): 25-35.
49. Dungen HD, Platzeck M, Vollert J, et al. Autoantibodies against cardiac troponin I in patients with congestive heart failure. Eur J Heart Fail 2010; 12(7): 668-75.
50. Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27.
51. Tang TT, Yuan J, Zhu ZF, et al. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res Cardiol 2012; 107(1): 232.
52. Wigren M, Bjorkbacka H, Andersson L, et al. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arte-rioscler Thromb Vasc Biol 2012; 32(8): 2000-4.
53. Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Transla-tional Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11(2): 119-29.
54. Timmers L, Sluijter JP, van Keulen JK, et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 2008; 102(2): 257-64.
55. Arslan F, Smeets MB, O'Neill LAJ, et al. Myocardial Ische-mia/Reperfusion Injury Is Mediated by Leukocytic Toll-Like Re-ceptor-2 and Reduced by Systemic Administration of a Novel Anti-Toll-Like Receptor-2 Antibody. Circulation 2010; 121(1): 80-90.
56. Arslan F, Houtgraaf JH, Keogh B, et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocar-dial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv 2012; 5(2): 279-87.
57. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997; 327 (Pt 1): 1-16.
58. Matsui Y, Ikesue M, Danzaki K, et al. Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ Res 2011; 108(11): 1328-39.
59. Vanhoutte D, Schellings MW, Gotte M, et al. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007; 115(4): 475-82.
60. Prockop DJ. Marrow stromal cells as stem cells for nonhema-topoietic tissues. Science 1997; 276(5309): 71-4.
61. Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America 2005; 102(32): 11474-9.
62. Quevedo HC, Hatzistergos KE, Oskouei BN, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proceedings of the National Academy of Sciences 2009; 106(33): 14022-7.
63. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of alloge-neic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012; 308(22): 2369-79.
64. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8(9): 726-36.
65. Dayan V, Yannarelli G, Billia F, et al. Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res Cardiol 2011; 106(6): 1299-310.
66. English K, French A, Wood KJ. Mesenchymal Stromal Cells: Facilitators of Successful Transplantation? Cell Stem Cell 2010; 7(4): 431-42.
67. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34+-Derived and Monocyte-Derived Dendritic Cells. The Journal of Immunology 2006; 177(4): 2080-7.
68. Duffy M, Ritter T, Ceredig R, Griffin M. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2: 34.
69. Rasmusson I, Ringdãn O, Sundberg B, Le Blanc K. Mesenchy-mal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76(8): 1208-13.
70. Huang XP, Sun Z, Miyagi Y, et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010; 122(23): 2419-29.
71. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006; 20(6): 661-9.
72. Mirotsou M, Zhang Z, Deb A, et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A 2007; 104(5): 1643-8.
73. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27(6): 1281-92.
74. Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail 2011; 13(11): 1161-71.
75. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122(1): 103-11.
76. Camelliti P, Green CR, Kohl P. Structural and functional coupling of cardiac myocytes and fibroblasts. Adv Cardiol 2006; 42: 132-49.
77. MacKenna D, Summerour SR, Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res 2000; 46(2): 257-63.
78. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004; 94(12): 1543-53.
79. Masur SK, Dewal HS, Dinh TT, Erenburg I, Petridou S. Myofibro-blasts differentiate from fibroblasts when plated at low density. Proc Natl Acad Sci U S A 1996; 93(9): 4219-23.
80. Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res 2000; 46(2): 250-6.
81. Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999; 97(2): 189-98.
82. Caulfield JB, Leinbach R, Gold H. The relationship of myocardial infarct size and prognosis. Circulation 1976; 53(3 Suppl): I141-4.
83. Murry CE, Reinecke H, Pabon LM. Regeneration gaps: observations on stem cells and cardiac repair. J Am Coll Cardiol 2006; 47(9): 1777-85.
84. Ino MDT, Nishimoto MDK, Okubo MDM, et al. Apoptosis as a Possible Cause of Wall Thinning in End-Stage Hypertrophic Car-diomyopathy. The American Journal of Cardiology 1997; 79(8): 1137-41.
85. Li RK, Jia ZQ, Weisel RD, et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 1996; 62(3): 654-60; discussion 60-1.
86. Menasche P, Hagege AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet 2001; 357(9252): 279-80.
87. Menasche P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117(9): 1189-200.
88. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardio-myocyte renewal in humans. Science 2009; 324(5923): 98-102.
89. Kajstura J, Urbanek K, Perl S, et al. Cardiomyogenesis in the adult human heart. Circ Res 2010; 107(2): 305-15.
90. Adler CP, Friedburg H. Myocardial DNA content, ploidy level and cell number in geriatric hearts: post-mortem examinations of human myocardium in old age. J Mol Cell Cardiol 1986; 18(1): 39-53.
91. Senyo SE, Steinhauser ML, Pizzimenti CL, et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature. [10.1038/nature11682] 2012; advance online publication.
92. Laflamme MA, Murry CE. Heart regeneration. Nature 2011; 473(7347): 326-35.
93. Mignone JL, Murry CE. A repair kit for the infarcted heart. Cell Stem Cell 2011; 8(4): 350-2.
94. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410(6829): 701-5.
95. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428(6983): 664-8.
96. Clifford DM FS, Brunskill SJ, Doree C, Mathur A, Watt S, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database of Systematic Reviews 2012(2): Art. No.: CD006536. DOI: 10.1002/14651858.CD006536.pub3.
97. Karantalis V, Balkan W, Schulman IH, Hatzistergos KE, Hare JM. Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol 2012; 303(3): H256-70.
98. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte pheno-type in the adult murine heart. Circulation 2002; 105(1): 93-8.
99. Zaruba MM, Soonpaa M, Reuter S, Field LJ. Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation 2010; 121(18): 1992-2000.
100. Jesty SA, Steffey MA, Lee FK, et al. C-kit+ precursors support postinfarction myogenesis in the neonatal, but not adult, heart. Proc Natl Acad Sci U S A 2012; 109(33): 13380-5.
101. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114(6): 763-76.
102. Dawn B, Stein AB, Urbanek K, et al. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A 2005; 102(10): 3766-71.
103. Williams AR, Hatzistergos KE, Addicott B, et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesen-chymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 2013; 127(2): 213-23.
104. Qian L, Huang Y, Spencer CI, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012; 485(7400): 593-8.
105. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142(3): 375-86.
106. Behfar A, Yamada S, Crespo-Diaz R, et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 2010; 56(9): 721-34.
107. Jayawardena TM, Egemnazarov B, Finch EA, et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fi-broblasts to cardiomyocytes. Circ Res 2012; 110(11): 1465-73.
108. Eulalio A, Mano M, Ferro MD, et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature. [10.1038/nature11739] 2012; advance online publication.
109. Masuda S, Shimizu T, Yamato M, Okano T. Cell sheet engineering for heart tissue repair. Adv Drug Deliv Rev 2008; 60(2): 277-85.
110. Sarig U, Machluf M. Engineering cell platforms for myocardial regeneration. Expert Opin Biol Ther 2011; 11(8): 1055-77.
111. Lakshmanan R, Krishnan UM, Sethuraman S. Living cardiac patch: the elixir for cardiac regeneration. Expert Opin Biol Ther 2012; 12(12): 1623-40.
112. Shimizu T, Yamato M, Isoi Y, et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ Res 2002; 90(3): e40.
113. Sekine H, Shimizu T, Hobo K, et al. Endothelial cell coculture within tissue-engineered cardiomyocyte sheets enhances neovascu-larization and improves cardiac function of ischemic hearts. Circulation 2008; 118(14 Suppl): S145-52.
114. Kobayashi H, Shimizu T, Yamato M, et al. Fibroblast sheets co-cultured with endothelial progenitor cells improve cardiac function of infarcted hearts. J Artif Organs 2008; 11(3): 141-7.
115. Frederick JR, Fitzpatrick JR, 3rd, McCormick RC, et al. Stromal cell-derived factor-1alpha activation of tissue-engineered endothe-lial progenitor cell matrix enhances ventricular function after myo-cardial infarction by inducing neovasculogenesis. Circulation 2010; 122(11 Suppl): S107-17.
116. Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopa-thy model. Circulation 2012; 126(11 Suppl 1): S29-37.
117. Xiong Q, Hill KL, Li Q, et al. A fibrin patch-based enhanced delivery of human embryonic stem cell-derived vascular cell transplantation in a porcine model of postinfarction left ventricular remodeling. Stem Cells 2011; 29(2): 367-75.
118. Zhang J, Klos M, Wilson GF, et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res 2012; 111(9): 1125-36.
119. Xu H, Yi BA, Wu H, et al. Highly efficient derivation of ventricular cardiomyocytes from induced pluripotent stem cells with a distinct epigenetic signature. Cell Res 2012; 22(1): 142-54.
120. Wong WT, Huang NF, Botham CM, Sayed N, Cooke JP. Endothe-lial cells derived from nuclear reprogramming. Circ Res 2012; 111(10): 1363-75.
121. Liao SY, Liu Y, Siu CW, et al. Proarrhythmic risk of embryonic stem cell-derived cardiomyocyte transplantation in infarcted myocardium. Heart Rhythm 2010; 7(12): 1852-9.
122. Shiba Y, Fernandes S, Zhu WZ, et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 2012; 489(7415): 322-5.
123. Beitnes JO, Hopp E, Lunde K, et al. Long-term results after intra-coronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart 2009; 95(24): 1983-9.
124. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009; 30(24): 2978-84.
125. Mansour S, Roy DC, Bouchard V, et al. One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction. Bone Marrow Res 2011; 2011: 385124.
126. Gyongyosi M, Lang I, Dettke M, et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med 2009; 6(1): 70-81.
127. Ge J, Li Y, Qian J, et al. Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction (TCT-STAMI). Heart 2006; 92(12): 1764-7.
128. Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355(12): 1222-32.
129. Meluzin J, Janousek S, Mayer J, et al. Three-, 6-, and 12-month results of autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction. Int J Cardiol 2008; 128(2): 185-92.
130. Tatsumi T, Ashihara E, Yasui T, et al. Intracoronary transplantation of non-expanded peripheral blood-derived mononuclear cells promotes improvement of cardiac function in patients with acute myocardial infarction. Circ J 2007; 71(8): 1199-207.
131. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myo-cardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J 2011; 32(14): 1736-47.
132. Roncalli J, Mouquet F, Piot C, et al. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J 2011; 32(14): 1748-57.
133. Tendera M, Wojakowski W, Ruzyllo W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009; 30(11): 1313-21.
134. Yousef M, Schannwell CM, Kostering M, Zeus T, Brehm M, Strauer BE. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 2009; 53(24): 2262-9.
135. Huikuri HV, Kervinen K, Niemela M, et al. Effects of intracoro-nary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008; 29(22): 2723-32.
136. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367(9505): 113-21.
137. Mocini D, Staibano M, Mele L, et al. Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting. Am Heart J 2006; 151(1): 192-7.
138. Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 2011; 109(4): 428-36.
139. Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on func-tional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012; 307(16): 1717-26.
140. Strauer BE, Brehm M, Zeus T, et al. Regeneration of human infarc-ted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 2005; 46(9): 1651-8.